Indaptus: Positive Safety Results in Multicancer Candidate Phase 1 Study

  Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort

• Single dose cohort data expected to be published at a scientific conference in 2024

https://www.globenewswire.com/news-release/2024/03/04/2839435/0/en/Indaptus-Therapeutics-Announces-Positive-Results-from-Second-Cohort-of-Phase-1-Trial-Company-Initiates-Multi-Dose-Cohort.html